An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 30, 2009

Primary Completion Date

August 19, 2010

Study Completion Date

August 19, 2010

Conditions
Crohn's DiseaseInflammatory Bowel Disease
Interventions
DRUG

AIN457

Trial Locations (5)

10029

Mount Sinai, One Gustave L. Levy Place, Box 1118, New York

11021

Long Island Clinical Research Associates, LLP, Great Neck

27612

Wake Research Asspcoates. ::C. 3100 Duraleigh Road, Suite 304, Raleigh

06010

Conneticut Gastroenterology Institute, 39 Brewster Road, Bristol

27599-7032

UNC School of Medicine, Room 7200 MBRB, 103 Mason Farm Road,, Chapel Hill

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY